GSK’s RSV vaccine candidate contains Agenus’ proprietary QS-21 STIMULON within its AS01 adjuvant, which – in the context of other antigens – has already demonstrated positive immune ...

GSK Licenses Shigella Vaccine altSonflex1-2-3 to Bharat Biotech: Strategic licensing agreement advances late-stage development and expands potential vaccine access in low- and middle-income countries.

On Friday, February 14, the FDA approved GSK plc’s (NYSE:GSK) Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25. The vaccine targets five major ...

Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine ...

GSK’s vaccine candidate, called altSonflex1-2-3, combines S. sonnei with S. flexneri 1b, 2a and 3a O Antigens, has been designed by scientists in the Global Health team with the ambition to ...

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners, by ...

GSK and Bharat Biotech have pledged to reduce the price of the world’s first malaria vaccine (RTS,S) through improved manufacturing efficiencies, expanded production and minimal profit margins ...

In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Stay updated with the latest news on Times of India.

As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices.

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

GSK expects to provide between 28- and 33 million doses of flu vaccine to the U.S. market this fall; about 23 million of that will come from the Quebec plant, Smolenaars Hunter said.